dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 28, 2026

UPS Releases 1Q 2026 Earnings

View original at finance.yahoo.com
“U.S. Domestic Segment 1Q 2026 Revenue $14,125 M”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • UPS expects to return to consolidated revenue and operating profit growth, and adjusted operating margin expansion in Q2 2026.

    60% confidence

  • U.S. Domestic Segment revenue declined 2.3% in Q1 2026, primarily driven by an expected decline in volume, while revenue per piece grew 6.5%.

    60% confidence

  • UPS employees around the world have worked hard and pushed the company's transformation forward.

    60% confidence

  • UPS reaffirms its full year 2026 financial guidance.

    60% confidence

  • Supply Chain Solutions revenue declined 6.5% in Q1 2026, primarily due to a decline in volume in the Mail Innovations business.

    60% confidence

  • International Segment revenue increased 3.8% in Q1 2026, driven by a 10.7% increase in revenue per piece.

    60% confidence

  • Q1 2026 was a critical transition period requiring flawless execution of several major strategic actions, which UPS successfully delivered.

    60% confidence

Data points we hold from this source

United Parcel Service · margin non gaap adjusted6.2 percent
United Parcel Service · eps non gaap adjusted1.07 USD
United Parcel Service · transformation charges after tax42 USD
United Parcel Service · net income1.27 USD
United Parcel Service · net income non gaap adjusted1.32 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
UPS Releases 1Q 2026 Earnings: Source | Via News | fr.via.news